Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation
NCT00668785Phase 2Terminated
- Sponsor
- Jumper
- Start
- Mar 2007
- Primary completion
- Jun 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in macular edema, sponsored by Jumper. Primary endpoint: Best Corrected Visual Acuity at 3 months. Started Mar 2007; status: terminated.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT00668785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668785.